Multiple BlueRun Ventures portfolio companies named to 2023 Future Healthcare 100 list

蓝驰创投蓝驰创投··0·0

Standing by founders from 0 to 1 to redefine the future.

The 2023 Future Healthcare 100 list was recently released.

This selection targets non-listed companies in the healthcare sector. Based on the VB100 valuation assessment model, the evaluation process involves company self-nomination, VB100 review committee assessment, cross-review by supporting institutions, and final review by the expert committee. From five major categories, the top 100 innovative companies by valuation are selected in each.

Multiple BlueRun Ventures portfolio companies made the list:

  • China Innovative Digital Healthcare

    BioMap

    ReviR Therapeutics

  • China Innovative Medical Devices

    ChengTian Technology

  • China Innovative Healthcare Services

    ShanZhen

    MediLink-Global

    Yaeher

  • Weilan Award - Leader Entrepreneur of the Year

    Wei Liu, Co-founder and CEO of BioMap

  • Value Sector Award - AI Drug Discovery

    ReviR Therapeutics

  • Value Sector Award - Health Insurance and Health Management

    MediLink-Global

Launched in 2015, the Future Healthcare 100 is China's first innovation-focused healthcare list targeting non-listed companies, developed by VB100, ArteryNet, and Eggshell Research Institute. It aims to identify Chinese healthcare innovators that truly represent the future, discover the core forces driving China's future healthcare industry, and promote innovation and transformation in the health and medical sector.

Guided by a technology-driven investment philosophy focused on finding next-generation biotech companies aligned with industry logic, BlueRun Ventures has already invested in multiple leading innovative enterprises across AI drug discovery, proteomics, advanced medical diagnostics, and cell therapy. BlueRun will continue to adhere to its early-stage technology investment strategy, supporting bold entrepreneurs who dare to redefine the future.

▶ More Content ◀

Originating in Silicon Valley, BlueRun Ventures was established in 2005 as a venture capital firm focused on early-stage startups.

BlueRun Ventures currently manages multiple USD and RMB dual-currency funds in China, with assets under management exceeding RMB 15 billion, making it one of the largest early-stage funds in the country. The firm invests primarily at Pre-A and Series A stages, covering hard tech and innovative interaction, enterprise technology, new consumer, and healthcare sectors. It has invested in over 150 startups, including Li Auto, Waterdrop, QingCloud, Guazi.com, Qudian, Songguo Mobility, Ganji.com, Energy Monster, Yuntu Semiconductor, Machenike, YunSheng Intelligence, Anxin Netshield, and BioMap.

BlueRun Ventures has been ranked #1 on Zero2IPO's "China Top 30 Early-Stage Investment Institutions" and ChinaVenture's "China Best Early-Stage Venture Capital Firms TOP30," and was named to Preqin's Global Top 10 VC Fund Managers for Consistent High Returns.

Additionally, BlueRun Ventures has received consecutive recognition from Forbes China, 36Kr, Cyzone, Caixin Media, CBNweekly, Jiemian, and other media organizations for honors including "China's Best Early-Stage Firm of the Year," "China's Top Venture Capital Firm," "Most Entrepreneur-Friendly Early-Stage Firm of the Year," and "Most Influential Early-Stage Firm of the Year."